B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction

J Cardiothorac Vasc Anesth. 2018 Jun;32(3):1500-1506. doi: 10.1053/j.jvca.2017.08.016. Epub 2017 Aug 9.

Authors

J Ross Renew¹, Nicole Cyrille², Ariel Yohai Elyahu³, Harish Ramakrishna⁴

Affiliations

¹ Mayo Clinic College of Medicine and Science, Jacksonville, FL.
² Department of Cardiology, Massachusetts General Hospital, Boston, MA.
³ Department of Internal Medicine, Mount Sinai Medical Center, New York, NY.
⁴ Mayo Clinic College of Medicine and Science, Phoenix, AZ. Electronic address: Ramakrishna.harish@mayo.edu.

PMID: 29373183
DOI: 10.1053/j.jvca.2017.08.016

No abstract available

Keywords: angiotension receptor- neprisilyn inhibitors (ARNI); heart failure; natriuretic peptides.

Publication types

Review

MeSH terms

Aminobutyrates / pharmacology
Aminobutyrates / therapeutic use
Angiotensin Receptor Antagonists / pharmacology
Angiotensin Receptor Antagonists / therapeutic use
Biphenyl Compounds
Disease Management*
Drug Combinations
Heart Failure / diagnosis
Heart Failure / drug therapy*
Heart Failure / physiopathology
Humans
Natriuretic Peptide, Brain / agonists
Natriuretic Peptide, Brain / physiology*
Signal Transduction / drug effects
Signal Transduction / physiology*
Stroke Volume / drug effects
Stroke Volume / physiology*
Tetrazoles / pharmacology
Tetrazoles / therapeutic use
Valsartan

Substances

Aminobutyrates
Angiotensin Receptor Antagonists
Biphenyl Compounds
Drug Combinations
Tetrazoles
Natriuretic Peptide, Brain
Valsartan
sacubitril and valsartan sodium hydrate drug combination